RxDoctor Payments Data

Lisa Laguna, NP

Family · Inglewood, CANPI 1750928388

Payments from drug & device makers

$1,125in general payments, 2019–2025

Across 47 payments — averaging $23.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$441
  • Boehringer Ingelheim$284
  • Novo Nordisk$103
  • Novartis$79
  • Exact Sciences$75
  • AbbVie$68
  • plus $75 from 3 others

What the payments were for

  • Food & beverage$1,09297%
  • Education$323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC15$441
Boehringer Ingelheim14$284
Novo Nordisk4$103
Novartis3$79
Exact Sciences4$75
AbbVie3$68
Amgen2$43
GSK1$17
Merck1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,125 in reported general payments places this provider in the 75th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$25,177
Medicare patients
147
Services billed
265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin49$61,241
TrulicityDulaglutide12$14,750
Atorvastatin Calcium146$927
Liothyronine Sodium12$752
Losartan Potassium96$745
Levothyroxine Sodium55$677
Amlodipine Besylate128$635
Albuterol Sulfate HfaAlbuterol Sulfate18$548
Rosuvastatin Calcium31$496
Metformin Hcl67$473
Lisinopril54$335
Valsartan12$301
Metoprolol Succinate14$240
ClopidogrelClopidogrel Bisulfate21$228
Omeprazole14$217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$284$61,24149 claims
Lilly USA, LLCTrulicity$441$14,75012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,634 family providers in California.

Other family in Inglewood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →